Journals / Southern Clinics of Istanbul Eurasia / 2020 / Cilt: 31 - Sayı: 4

Short-Term Results of Ahmed Glaucoma Valve Implantation in Refractory Glaucoma

Pages
350–355
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Longer follow up will show the sustainable impact of AGV implantation on IOP.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to evaluate short-term outcomes of Ahmed glaucoma valve (AGV) (New World Medical Inc., Rancho Cucamonga, CA, USA) implantation in cases of refractory glaucoma.
📊
Key Findings & Data:Methods: The records of 31 patients who underwent AGV implantation between January 2018 and March 2019 for refractory glaucoma were retrospectively evaluated.
💡
Conclusion & Impact:Longer follow up will show the sustainable impact of AGV implantation on IOP.
🔬Design:Research Article
📍Scope:2018 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to evaluate short-term outcomes of Ahmed glaucoma valve (AGV) (New World Medical Inc., Rancho Cucamonga, CA, USA) implantation in cases of refractory glaucoma. Methods: The records of 31 patients who underwent AGV implantation between January 2018 and March 2019 for refractory glaucoma were retrospectively evaluated. Patients with a visual acuity of at least light perception and postoperative follow-up records of at least 6 months were included in the study. Preoperative and postoperative best corrected visual acuity (BCVA), intraocular pressure (IOP), number of topical antiglaucoma medications used, and central corneal thickness (CCT) measurements were recorded, as well as any postoperative complications. Results: The surgical outcome was graded as complete success for an IOP of 5 to 22 mmHg without antiglaucomatous medication, qualified success for an IOP of 5 to 2 mmHg with antiglaucomatous medication, or failure for an IOP >22 mmHg despite medication. The sum of the complete success and qualified success groups was considered the total success rate. The mean length of follow-up was 12.94±4.98 months. The preoperative mean IOP level and number of topical antiglaucoma medications had decreased from 40.84±8.27 mmHg to 13.84±2.95 mmHg and 3.68±0.54 to 1.10±1.35, respectively, at the final postoperative examination. There were no significant differences between the preoperative and postoperative CCT and BCVA values (p>0.05). The most common (n=3) complication was encapsulated cyst formation in the AGV plate region. The complete, qualified, and total success rates were 45.2% (n=14), 54.8% (n=17) and 100% (n=31), respectively. Conclusion: Although the mean preoperative IOP level is typically quite high in refractory glaucoma cases, AGV implantation is an effective surgery for reducing IOP in the short term. Longer follow up will show the sustainable impact of AGV implantation on IOP.

🔖

Cite This Article

ŞİMŞEK, Ş., GÜN, R. D. (2022). Short-Term Results of Ahmed Glaucoma Valve Implantation in Refractory Glaucoma. Southern Clinics of Istanbul Eurasia, Cilt: 31 - Sayı: 4, 350–355. https://ajindex.com/articles/592783

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262−67
  2. Das JC, Chaudhuri Z, Sharma P, Bhomaj S. The Ahmed glaucoma valve in refractory glaucoma: Experiences in Indian eyes. Eye (Lond) 2005;19:183–90
  3. Lima FE, Magacho L, Carvalho DM, Susanna R Jr, Avila MP. A prospective, comparative study between endoscopic cyclophotocoagulation and the Ahmed drainage implant in refractory glaucoma. J Glaucoma 2004;13:233–37
  4. Syed HM, Law SK, Nam SH, Li G, Caprioli J, Coleman A. Baerveldt- 350 implant versus Ahmed valve for refractory glaucoma: A case-controlled comparison. J Glaucoma 2004;13:38–45
  5. Rosenberg LF, Krupin T. Implants in glaucoma surgery. In: Ritch R, Shields MB, Krupin T, editors. The Glaucomas. 2nd ed. Philadelphia: Mosby; 1996. p. 1783−807
  6. Bakbak B, Ersoy G, Önder F. Tedaviye dirençli glokom olgularında Ahmed glokom valv implantasyonu. Kartal Eğitim ve Araştırma Hastanesi Tıp Dergisi 2008:19:62−6
  7. Yazgan S, Çelik U, Uğurbaş SC, Bayraktar Ş, Yılmaz ÖF. Dirençli glokom vakalarında Ahmet glokom valf implantasyonunun uzun dönem klinik sonuçları, Medeniyet Medical Journal 2016:31:15−22
  8. Allingham RR, Damji K, Freedman S, Moroi S, Shafranov G, Shields MB. Shields’ Textbook of Glaucoma. 5th ed. Philadelphia: LippincottWilliams & Willkins; 2005. p. 610−23
  9. Francis BA, Cortes A, Chen J, Alvarado JA. Characteristics of glaucoma drainage implants during dynamic and steady-state flow conditions. Ophthalmology 1998;105:1708−14
  10. Coleman AL, Hill R, Wilson MR, Choplin N, Kotas-Neumann R, Tam M, et al. Initial clinical experience with the Ahmed glaucoma valve implant. Am J Ophthalmol 1995;120:23−31
  11. Wilson MR, Mendis U, Smith SD, Paliwal A. Ahmed glaucoma valve implant vs. trabeculectomy in the surgical treatment of glaucoma: A randomized clinical trial. Am J Ophthalmol 2000;130:267−73
  12. Coleman AL, Smyth RJ, Wilson MR, Tam M. Initial clinical experience with the Ahmed glaucoma valve implant in pediatric patients. Arch Ophthalmol 1997;115:186–91
  13. Law SK, Nguyen A, Coleman AL, Caprioli J. Comparison of safety and efficacy between silicone and polypropylene Ahmed glaucoma valves in refractory glaucoma. Ophthalmology 2005;112:1514−20
  14. Moschos MM, Nitoda E, Gouliopoulos N, Androudi S, Damaskos C, Laios K, et al. The Choice of Drainage Device in Complicated Glaucomas: Comparing Ahmed and Baerveldt Implants. In Vivo 2019;33:911−16
  15. Elhefney E, Mokbel T, Samra WA, Ki